, Tracking Stock Market Picks
Enter Symbol:
Acadia Pharmaceuticals Inc. (ACAD) [hlAlert]

up 351.30 %

Acadia Pharmaceuticals Inc. (ACAD) rated Buy with price target $23 by Fortis Bank

Posted on: Friday,  Mar 7, 2008  12:25 PM ET by Fortis Bank

Fortis Bank rated Buy Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) on 03/07/2008, when the stock price was $8.40. Since
then, Acadia Pharmaceuticals Inc. has gained 351.31% as of 01/25/2016's recent price of $37.91.
If you would have followed this Fortis Bank's recommendation on ACAD, you would have gained 351.3% of your investment in 2880 days.

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company is developing a portfolio consisting of its four product candidates, including pimavanserin, which is in Phase III development for the treatment of Parkinson?s disease psychosis. In addition, the Company has a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma, both in collaboration with Allergan, Inc., and ACP-106 in IND-track development. The Company?s product candidates include Pimavanserin, AGN-XX/YY, AC-262271 and ACP-106. The Company maintains two wholly owned subsidiaries: ACADIA Pharmaceuticals AB based in Malmo, Sweden and ACADIA Pharmaceuticals A/S based in Denmark.

We are a global asset manager, offering investment solutions to clients in many different segments and markets. First and foremost, we are an active manager: we aim to deliver superior returns to our clients by making considered investment decisions based upon our own research. As well as seeking out the most rewarding top-down and bottom-up sources of returns, our investment centres carefully manage the risk in their portfolios. Risk budgeting and risk allocation are key elements in all of our investment strategies. We implement our strategies through model portfolios, which are adjusted in line with the investment objectives and constraints of individual clients. Intelligent implementation is an important determinant of final performance.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/7/2008 12:25 PM Buy
8.40 23.00
as of 12/24/2008
1 Week down  -12.84 %
1 Month down  -1.04 %
3 Months down  -12.03 %
1 YTD up  5.55 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy